ONCE Spark Therapeutics Inc.

+0.81  (+2%)
Previous Close 39.28
Open 38.8
Price To Book 2.75
Market Cap 1513281921
Shares 37,747,117
Volume 328,194
Short Ratio
Av. Daily Volume 644,390

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated late 2018. Phase 1/2 data updated data at ASH 2018 noted stable factor VIII activity levels in lower dose cohorts but high dose cohort data not noted. Further data due mid-2019.
Hemophilia A
Phase 1/2 updated data released May 22, 2018 - 98% decrease in bleeding rate.
Hemophilia B
Phase 1/2 update YE 2018.
SPK-7001 (SPK-CHM)
PDUFA date January 12, 2018 under priority review. Advisory Committee Meeting October 12, 2017 voted 16-0 in favor of recommending approval. Approval announced December 19, 2017.
Luxturna (voretigene neparvovec)
Inherited retinal dystrophies
Phase 3 lead-in trial initiation announced July 16, 2018.
FIX Replacement therapy
Hemophilia B

Latest News

  1. See what the IHS Markit Score report has to say about Spark Therapeutics Inc.
  2. Spark Therapeutics CEO on breakthroughs in gene therapy
  3. Spark Therapeutics Announces Updated Data on SPK-8011 from Ongoing Phase 1/2 Dose-escalation Clinical Trial in Hemophilia A at 60th American Society of Hematology (ASH) Annual Meeting and Exposition
  4. Bayer To Cut 12,000 Jobs Amid Strategic Overhaul To Focus On Pharma
  5. Biotech Stock Roundup: Pipeline Updates From CELG & VRTX, ZFGN Plunges on Hold News
  6. Analysis: Positioning to Benefit within Real Goods Solar, Natural Resource Partners LP, Spark Therapeutics, Social Reality, Rapid7, and BiondVax Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
  7. Spark Therapeutics' Luxturna Gets EU Approval for Vision Loss
  8. European approval of Spark Therapeutics' gene therapy triggers $25M payment
  9. Is Spark Therapeutics Inc’s (NASDAQ:ONCE) CEO Being Overpaid?
  10. European Commission Approves Spark Therapeutics’ LUXTURNA® (voretigene neparvovec), a One-time Gene Therapy for Inherited Retinal Disease Caused by Confirmed Biallelic RPE65 Mutations
  11. Edited Transcript of ONCE earnings conference call or presentation 6-Nov-18 1:30pm GMT
  12. Analyzing Editas Medicine’s Operational Performance
  13. Editas Stock: Analysts’ Recommendations
  14. Who’s Eyeing Editas Medicine?
  15. uniQure Stock Rose 35.7% Yesterday—Here’s Why
  16. Sangamo stock drops after J.P. Morgan downgrade
  17. These Biopharmas Could Cure Genetic Diseases — At $5 Million Apiece

SEC Filings

  1. CT ORDER - Confidential treatment order 181213884
  2. 8-K - Current report 181199141
  3. 8-K - Current report 181186080
  4. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
  5. CT ORDER - Confidential treatment order 181169488
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 181163508
  7. 8-K - Current report 181161524
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 18999793
  9. 8-K - Current report 18996333
  10. 8-K - Current report 18944901